EA
IMVT icon

Evolution Advisers’s Immunovant IMVT Stock Holding History

Evolution Advisers’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+4
New +$122 ﹤0.01% 527

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Evolution Advisers's IMVT Position: Q2 2026 in Review

Evolution Advisers opened a new position in Immunovant (IMVT) in Q2 2026: 4 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #527 among its holdings.

225 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Evolution Advisers held 4 shares of Immunovant worth $0 as of Q2 2026.
  • Immunovant was a new Evolution Advisers position in Q2 2026.
  • Immunovant made up ﹤0.01% of Evolution Advisers's portfolio in Q2 2026, its #527 holding.
  • 225 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Evolution Advisers's 13F filing for Q2 2026, filed 31 Jul 2026.